Search this site

Dubai, UAE — 3 February 2026 — Actxa, a Singapore-based preventive health brand committed to making preventive healthcare more accessible and actionable, will be participating in World Health Expo (WHX) Dubai 2026. At the event, Actxa will showcase its Core Smart Ring, featuring AI Glucose Scan capabilities designed to support everyday metabolic health awareness. Introducing Actxa: Advancing Preventive Health Through Wearable Intelligence Actxa’s mission is simple but urgent – empower individuals with meaningful, health insights that enable earlier intervention and better long-term outcomes. By combining wearable technology, artificial intelligence and clinically backed technologies, Actxa aims to bridge the gap between everyday wellness tracking and true preventive care. Spotlight at WHX Dubai: Core Smart Ring with AI Glucose Scan At WHX Dubai, Actxa will highlight the Core Smart Ring, a sleek and comfortable wearable designed for continuous lifestyle monitoring. Featuring AI Glucose Scan powered by Actxa’s proprietary BGEM® Glucose Status technology, the Core Smart Ring provides users with smarter insights related to glucose status patterns. BGEM® is the world’s first non-invasive, AI-driven glucose evaluation technology, supported by clinical studies. By analysing photoplethysmography (PPG) data from the Core Smart Ring, BGEM® delivers meaningful, pain-free glucose insights without the need for needles or blood samples. With a quick 1-minute scan, users receive a clear “Normal” or “Elevated” result linked to daily habits, with results syncing seamlessly to the Actxa App, where insights are presented through a clean, intuitive interface. Paired with lifestyle guidance that is easy to read and easy to act on, the Core Smart Ring supports smarter daily health decisions. Key features of the Core Smart Ring include: · Clinically backed BGEM® technology · Fast, one-minute scans · No needles, no pain · An ultra-light, durable titanium design Engaging the Ecosystem at WHX Dubai Actxa is participating in WHX Dubai to engage regional and global stakeholders across healthcare, wellness and technology. Through its participation, Actxa aims to connect with partners who share a common vision for advancing preventive health through innovation. Actxa looks forward to partnership opportunities with: · Distributors expanding next-generation wearables across retail, pharmacy and healthcare channels · Healthcare and wellness partners exploring innovative solutions in metabolic health and preventive screening · Strategic partners and investors aligned with the convergence of AI, wearables and chronic disease prevention Driving Preventive Health Forward “Preventive health starts with awareness, but real impact comes from how insights are turned into everyday action,” said Marcus Soo, CEO of Actxa. “With the Core Smart Ring and our BGEM® technology roadmap, we aim to empower individuals, partners and healthcare stakeholders with actionable insights that support earlier intervention, better decision-making and long-term health outcomes.” A Peek into the Future: A Preventive Health Pipeline for BGEM® Technology Beyond the Core Smart Ring, Actxa continues to advance its BGEM® technology roadmap. Actxa will also preview its upcoming BGEM®, a pain-free, one-minute measurement solution that provides dynamic blood glucose range insights, representing the next phase of its preventive health technology portfolio. Visit Actxa at WHX Dubai Actxa invites attendees to experience its preventive health solutions firsthand at Booth #N23.E74 throughout WHX Dubai and explore opportunities for collaboration, distribution and strategic partnerships. About Actxa Actxa is a preventive health brand creating smart wearables and devices that help people understand their health and live well every day. Backed by our own team of researchers and proprietary health technologies, including BGEM®, the world’s first non-invasive, clinically backed AI-driven blood glucose evaluation and monitoring technology. Actxa turns complex body signals into simple, meaningful insight that supports healthier choices and long-term wellbeing.

Singapore, 13 May 2022 – Actxa Pte.Ltd (“Actxa”), a homegrown AI-driven preventive health solutions company, has been awarded the SBR Technology Excellence Award in the AI – Healthcare Technology category for its Non-Invasive Blood Glucose Monitoring (“BGM”) project. Actxa is the first Singapore company to develop a comprehensive AI solution that leverages consumer-grade wearables to detect blood glucose dysregulation. The BGM is also the only non-invasive blood glucose evaluation solution to be going through a clinical validation study in Southeast Asia. The latest Singapore National Population Health Survey shows that 9.5% of adults have diabetes from 2019 to 2020. Nearly a quarter of them are newly diagnosed, whilst 26% exhibit poor glucose control¹. In 2017, the Singapore Ministry of Health launched a nationwide initiative to tackle the epidemic of diabetes, and advances in wearable technologies may be the key to alleviating this problem. As a company with a vision to be a leading preventive health technology company in the world, Actxa’s research and development (“R&D”) team began working on a novel digital monitoring technology in 2016, which was later coined as BGM. Its goal was to engineer a solution that is non-invasive, frequently and conveniently accessible, and low cost. The innovative non-invasive BGEM® solution uses advancements in signal processing, wearable technology and artificial intelligence (“AI”) to generate glucose-related insights from physiological signals. Using inter-beat interval data captured through a consumer-grade wrist-worn photoplethysmography (“PPG”) sensor, the AI model analyses relevant digital biomarkers associated with glucose patterns. These insights can help support greater glucose awareness and provide individuals with a better understanding of how their body may respond to everyday lifestyle factors. Joel Chin, Actxa’s Chief Executive Officer, said, “It is a great honour of Actxa to be a recipient of the SBR Technology Excellence Awards 2022. We want to thank the Singapore Business Review and the judges for recognising Actxa’s accomplishments. This is the best form of recognition for the R&D team who has been working on this project for the past five years. It is a testament of our commitment to being at the forefront of innovation, and we will continue doing so for the betterment of public health.” This technology is undergoing conducting a clinical validation study with a local hospital to improve the prediction model and evaluate the model’s real-world accuracy, reliability, and generalisability. The BGEM will be available as a B2B cloud service with the production of at least one wearable product by quarter four of 2022. About Actxa Actxa was founded in 2015 with the mission to bring together people, partners, science, technology, and data to create positive changes to the health, quality of life and well-being of individuals and communities. Leveraging on our expertise in developing evidence-based and personalised insights through Artificial Intelligence, we empower individuals to make informed decision on their health and well-being and to make timely changes to their lifestyle. Actxa sets its focus on research and development on innovative preventive health solutions and we work closely with industry and academic partners to explore new opportunities. About SBR Technology Excellence Awards Organised by the Singapore Business Review, the SBR Technology Excellence Awards is the most prestigious awards programme for technological innovations, recognising exceptional companies in Singapore that are riding the digital disruption wave and leading the technological revolution and digital journeys of their respective industries. The SBR Technology Excellence Awards is part of the regional Asian Technology Excellence Awards now running in 50 countries. References: [1] National Population Health Survey 2020, MOH. https://www.moh.gov.sg/docs/librariesprovider5/default-document-library/nphs-2020-survey-report.pdf. For further information, please contact: Tan Lay Eng Corporate Communications Manager layeng.tan@actxa.sg +65 9877 0406

For immediate release Singapore, 27 September 2021 – Actxa and KK Women’s and Children’s Hospital (KKH) are carrying out a clinical study to validate a non-invasive blood glucose predictive model on wearable devices with photoplethysmography (PPG) sensors developed by Actxa. The roles of wrist-worn and in-ear wearables with PPG sensors are constantly evolving. From being a lifestyle device that monitors sports and activities, to a device that monitors a person’s lifestyle well-being and health, foraying into preventive healthcare, particularly for the prevention of chronic diseases. Diabetes has been one of the “silent” chronic diseases, and research has shown that diabetic patients have a two to three-fold higher risk of developing cardiovascular disease. In Singapore and globally, diabetes and cardiovascular diseases are serious health concerns resulting in poor quality of life. Leveraging on its expertise and knowledge of wrist-worn and in-ear wearables, Actxa has developed a predictive model based on Artificial Intelligence and Machine Learning (AIML) for PPG sensors to monitor blood glucose level non-invasively. The collaboration with KKH will enable Actxa to externally validate its predictive model against an independent population, helping to further evaluate and improve the model’s performance and robustness. Joel Chin, CEO of Actxa, said, “We are excited about this collaboration as it will help strengthen our understanding of how non-invasive physiological signals can support greater glucose awareness and provide more accessible health insights. It will also offer valuable insights into the potential of wearables to provide continuous, real-time physiological data that can help individuals better understand their glucose-related patterns and make more informed choices about their everyday health and lifestyle.” Associate Professor Ang Seng Bin, Head and Senior Consultant, Family Medicine Service, KKH, who is also the principal investigator of this research at KKH, said, “As Singapore’s largest academic medical centre specialising in women’s and children’s health, KKH is committed to improving patient health outcomes. Through this new collaboration, we hope that we can harness the power of technology to make a difference in patients’ lives.” This clinical study will be carried out jointly by the following Principal Investigators – Associate Professor Ang Seng Bin (KKH), Emeritus Professor Satvinder Singh Dhaliwal (Actxa) and Mr Shi Bohan (Actxa). Results and findings from this clinical study are to be published in the second half of 2022 in peer-reviewed scientific journals. Actxa will carry out more clinical trials in the near future to provide further clinical evidence for new products. About Actxa Headquartered in Singapore, Actxa Pte.Ltd (“Actxa”) was founded in 2015 with the mission to have deep empathy and harness the power of science and data to empower people to lead healthier lives. At Actxa, we inspire individuals from all walks of life to make proactive moves to live better and healthier. Leveraging data analytics, artificial intelligence, and machine learning, we create evidence-based, personalised health insights in the domains of physical activities, sleep quality, body composition, stress and recovery, heart health and non-invasive blood glucose monitoring. With the help of these insights, Actxa develops applications such as Healthy Living Score (HLS), Actxa Wellness Programme (AWP) and products to empower individuals to manage and improve their own health. Good health and happiness go hand-in-hand. Actxa is committed to taking the lead to create Better Moves, Better Lives to better ourselves, the people around us and our community. For further information, please contact: Tan Lay Eng Corporate Communications Manager layeng.tan@actxa.com +65 98770406

Singapore, 23 October 2025 - Actxa is excited to participate in TechInnovation 2025, Asia’s premier platform for innovation and business transformation, organised by IPI Singapore, where we will showcase BGEM, our AI-driven, non-invasive blood glucose evaluation technology that advances the frontier of preventive health innovation. BGEM® leverages AI to provide non-invasive glucose insights, helping individuals build greater awareness of their glucose patterns and better understand how everyday factors such as diet, activity and lifestyle may influence their wellbeing. These insights can support more informed health choices and long-term wellness. The technology reflects Actxa’s commitment to developing science-based solutions that make preventive health more accessible and relevant to everyday life. Learn how Actxa’s AI-driven BGEM technology is shaping the future of preventive health. Speaker Session Topic: BGEM: AI for diabetic risk screening and control Speaker: Dr. Du Yao, Head of Research and Development, Actxa Date and Time: 30 Oct, Thursday at 3.30pm Event Details Date: 29 – 31 October 2025 Location: Sands Expo & Convention Centre, Level 3, Heliconia Ballroom Stand: K02 Visit our stand to learn more about BGEM and connect with our team to explore how Actxa is shaping the future of preventive health through innovation. Keen to speak with our team and explore collaboration opportunities? Secure your meeting slot https://forms.office.com/r/qhTpjtSQed

Singapore, 14 March 2025 – Actxa Pte Ltd, a pioneer in AI-driven preventive healthcare, has been recognised as the Best AI-Driven Preventive HealthTech Company 2025 at the Singapore Business Awards hosted by APAC Insider. This award celebrates Actxa's dedication to improving health through technology, especially in the growing field of preventive healthcare. This recognition highlights Actxa’s mission to create next-generation preventive health solutions using artificial intelligence (“AI”) and data analytics. BGEM® is Actxa’s proprietary non-invasive glucose evaluation technology, designed to provide greater glucose awareness and help users better understand how everyday factors such as diet, activity and lifestyle may influence their wellbeing. By making these insights more accessible, BGEM® empowers individuals to make more informed choices about their everyday health. “Receiving the Best AI-Driven Preventive HealthTech Company award is an immense honour for us,” said Marcus Soo, CEO of Actxa. “I would like to dedicate this award to our team for their hard work, commitment, and visionary approach. Preventive health is at the heart of everything we do, giving people personalised, real-time insights using AI so they can make healthier decisions.” Actxa’s impact doesn’t stop with individual health. The company is also aligned with Singapore’s Healthier SG initiative, which aims to shift the focus of healthcare toward prevention. With tools like VO2 Max measurement and Sleep Track™, Actxa empowers people with the knowledge to lead healthier, more active lives. At Actxa, the focus is on more than just technology—it is about using innovation to improve the well-being of individuals and communities. Their core values—innovation, excellence, integrity, empathy, and inclusiveness—are reflected in every product, from BGEM technologies to the Sense 2 Smart Scale and Spark+ Series 2 fitness trackers. At its core, Actxa is driven by a vision to help people live healthier and longer with technology. For further information, please contact: ​Tan Lay Eng Communications Manager layeng.tan@actxa.com +65 9877 0406 Hasyimah Begum AJ Communications Executive hasyimah.aj@actxa.com +65 8780 3620  About Actxa Headquartered in Singapore, Actxa Pte Ltd is a deep tech company founded in 2015 that leverages artificial intelligence to create next generation preventive healthcare solutions. ​ We create evidence-based, personalised health insights in the domains of physical activities, sleep quality, body composition, stress and recovery, heart health and blood glucose evaluation and monitoring. ​​ ​Learn more about Actxa at www.actxa.com.

4 April 2024 – Actxa Pte Ltd (“Actxa”), an AI-driven deep tech company headquartered in Singapore, has signed a Memorandum of Agreement (“MOU”) with Instytut Medycyny Innowacyjnej sp.z o.o. (“IMI”), a research and medical technologies institute based in Poland on 7 March 2024. This MOU marks the beginning of a strategic partnership for collaboration and market distribution of Actxa’s BGEM, a non-invasive blood glucose evaluation technology and other Actxa technologies in Poland. At the heart of this partnership is Actxa’s groundbreaking BGEM technology - the world’s first non-invasive blood glucose evaluation technology. Harnessing the power of artificial intelligence ("AI"), wearable technologies and signal processing, BGEM tracks and identifies diabetes risk. By analysing inter-beat-interval data from consumer-grade wearables equipped with photoplethysmography ("PPG") sensors, BGEM calculates the digital biomarkers associated with prediabetes or Type 2 diabetes mellitus ("T2DM") symptoms, empowering users to monitor, track, and identify their diabetic risk. This proactive approach allows users to implement timely lifestyle adjustments, effectively mitigating the risk or delaying the onset of diabetes. Under this partnership, IMI will be an authorised licensee with the rights to use BGEM and incorporate the technology in its brand of wearable products for distribution in Poland. Additionally, IMI will play a pivotal role in facilitating the exploration of opportunities within countries, governments and industries to sell and market wearables with BGEM and other Actxa technologies. Marcus Soo, Chief Executive Officer of Actxa, said, “Our collaboration with IMI signifies an important milestone in our journey toward global expansion. This collaboration is a testament to our commitment to innovation and excellence in the tech industry. Together with IMI, we embark on a transformative endeavour, combining our strengths to propel our business to new heights internationally. This alliance not only strengthens our position in the global market but also allows our technologies, such as BGEM, to benefit a broader community. As we join forces with IMI, we are poised for unparalleled growth, setting the stage for a future defined by international success and groundbreaking achievements.” Founder of IMI, Professor Mieczysław Pasowicz shared, “At IMI, we are driven by a shared vision for a future where healthcare is transformed through innovation. Our collaboration with Actxa speaks to our unwavering dedication as we bring their groundbreaking technologies to Poland. Our strategic partnership aims to revolutionise healthcare, fostering a future where cutting-edge solutions positively impact lives. This partnership represents a significant stride towards a healthier and more technologically advanced world.” This alliance between Actxa and IMI sets the stage for Actxa’s innovative technologies to expand globally. As both companies continue to leverage their strengths and expertise, they are poised to drive positive change and contribute to the advancement of a healthier world. For further information, please contact: ​Tan Lay Eng Communications Manager layeng.tan@actxa.com +65 9877 0406 Hasyimah Begum AJ Communications Executive hasyimah.aj@actxa.com +65 8780 3620  About Actxa Headquartered in Singapore, Actxa Pte Ltd is a deep tech company founded in 2015 that leverages artificial intelligence to create next generation preventive healthcare solutions. ​ We create evidence-based, personalised health insights in the domains of physical activities, sleep quality, body composition, stress and recovery, heart health and blood glucose evaluation and monitoring. ​​ ​Learn more about Actxa at www.actxa.com. About Instytut Medycyny Innowacyjnej sp.z o.o For nearly 30 years Prof. Mieczysław Pasowicz has been creating and implementing initiatives related to the adaptation of hospitals to European Union standards through the creation and implementation of innovative investment projects. He specializes in investment and hospital development, healthcare management and training and digital transformation. It promotes the development of personalized medicine, coordinated healthcare and digital medicine. This is possible thanks to the involvement in modern technologies, advanced treatment methods and continuous training of medical personnel. Prof. Mieczysław Pasowicz is the founder and president/CEO of the Institute. The Institute of Innovative Medicine is a spin-off company established to commercialize research and implement new medical technologies. The company is the initiator of the creation of the BioMedTech Technology Park, the aim of which is to transfer technology from Asia to Europe and is currently looking for Partners and Investors interested in co-creating the Longevity Technology Park using the latest developments in medical robotics, biotechnology, IT, artificial intelligence and other medical technologies. It already has a modern facility with an area of 18 thousand m2 and an investment area for the creation of the Park (www.medtechpoland.eu). Leading programs promoting organizational, product and technological innovations, the Institute of Innovative Medicine together with its partners achieves better results and market position in many areas. The Institute provides consulting and training services, provides specialized IT systems and medical equipment and offers management of healthcare facilities. It has several medical teams and cooperates with more than 100 specialists both at home and abroad. The Institute and BioMedTech Park will support young companies, innovative products and proven technologies, introducing them to domestic and international markets on behalf of customers and through sales programs. Prof. Dr hab. med. Mieczysław Pasowicz is a long-time director of the John Paul II Hospital in Krakow and vice-president of the European Association of Hospital Managers (EAHM). He is the founder and also serves as the president of the Polish Association of Hospital Directors. Prof. Pasowicz is a long-term academic lecturer with significant medical, scientific and organizational achievements.

Actxa CEO, Marcus Soo (right) and Dr Abhinav (left) embarking on a new partnership. 10 June 2024 – Actxa Pte Ltd (“Actxa”), a Singaporean AI-driven deep tech company, has entered a Memorandum of Understanding (“MOU”) with the Diabetes and Hypertension Clinic (“DHC”) in India, a diabetes evaluation and management centre. The MOU, signed on 6 June 2024, marks a strategic step for Actxa to further research on diabetes prevention with artificial intelligence (“AI”) in India. Since 2017, Actxa has been collaborating with research and medical institutions in Singapore in the research and development of non-invasive technology glucose evaluation technology. The company completed its first clinical trial in 2022 and published its first scientific paper in 2023. Actxa’s BGEM is the world’s first non-invasive solution powered by an AI-driven algorithm that enables wearables and hearables with Photoplethysmography (PPG) sensors to assess glucose status. In India, an estimated 77 million people above the age of 18 suffer from T2DM, with nearly 25 million classified as prediabetic [1]. Individuals with diabetes are at a higher risk for serious health issues, including heart attack, stroke and kidney failure. Over time, T2DM can damage blood vessels in the heart, eyes, kidneys and nerves [2]. This MOU seeks to broaden the study of non-invasive solution using artificial intelligence in the Indian population. If successful, the non-invasive solution will be an affordable and user-friendly approach to promoting frequent monitoring of diabetic risk in India. Marcus Soo, Chief Executive Officer of Actxa, said, “We are happy to work with like-minded professionals like Dr. Abhinav Gupta of DHC. This collaboration showcases commitment from both Actxa and DHC, and our dedication to improving the lives of individuals affected by diabetes through innovation and excellence using advanced science and AI technology. Together with DHC, we aim to empower individuals in India with valuable insights into their diabetic health.” Dr. Abhinav Gupta, MBBS, MD, FRCP, Professor of Medicine at ASCOMS, shared, “Our collaboration with Actxa represents a pivotal milestone in our journey in advancing diabetes prevention and care. Through research on AI-based algorithms for detecting hyperglycemia in diabetes patients, we are poised to make significant strides in early detection and treatment. This partnership underscores our dedication to harnessing cutting-edge technology for better health outcomes, aligning with the innovative BGEM technology.” This collaboration between Actxa and DHC paves the way for groundbreaking advancements in diabetes prevention and care, contributing to a healthier future for individuals in Singapore, India and worldwide. References: 1. World Health Organization, Diabetes in India: https://www.who.int/india/health-topics/mobile-technology-for-preventing-ncds 2. World Health Organization, Diabetes: https://www.who.int/news-room/fact-sheets/detail/diabetes For further information, please contact: ​Tan Lay Eng Communications Manager layeng.tan@actxa.com +65 9877 0406 Hasyimah Begum AJ Communications Executive hasyimah.aj@actxa.com +65 8780 3620  About Actxa Headquartered in Singapore, Actxa Pte Ltd is a deep tech company founded in 2015 that leverages artificial intelligence to create next generation preventive healthcare solutions. ​ We create evidence-based, personalised health insights in the domains of physical activities, sleep quality, body composition, stress and recovery, heart health and blood glucose evaluation and monitoring. ​​ ​Learn more about Actxa at www.actxa.com. About Diabetes and Hypertension Clinic Diabetes and Hypertension Clinic is a daycare setting run by Dr. Abhinav Gupta, who is a pioneer in the management of Diabetes and Hypertension. He has more than 15 years of experience in DHC, which is located in Channi Himmat Jammu, J&K, India. Dr. Gupta has been awarded a fellowship of the Royal College of Physicians of London, Edinburgh and Glasgow.

25 July 2024 – Actxa Pte Ltd (“Actxa”), a Singaporean AI-driven deep tech company, has entered a Memorandum of Understanding (“MOU”) and a Research and Collaboration Agreement (“RCA”) with Universitas Kristen Krida Wacana (“UKRIDA”), a prominent private institution of higher education that has been committed to education, research, and community service for 56 years in Indonesia, with its Faculty of Medicine and Health Sciences being the oldest at the university. The MOU and RCA, signed on 24 July 2024, mark a significant milestone for Actxa as it embarks on a collaborative partnership focusing on joint research, product development, higher education, human resources development, and community services in artificial intelligence (“AI”) based chronic disease management. UKRIDA, whose mission is to be at the forefront of healthcare science development, has embraced Artificial intelligence as an avant-garde, innovative technology as a major focus for UKRIDA’s Research and Development efforts. This joint project, therefore, will bring great benefit to both Actxa and UKRIDA, whose interests are perfectly matched. Since 2017, Actxa has been at the forefront of collaborations with research and medical institutions in Singapore and globally, focusing on developing life-changing preventive health technologies and solutions using AI. One of Actxa’s most significant achievements is BGEM, the world’s first non-invasive glucose evaluation technology. Powered by a cloud-based AI-driven algorithm, BGEM integrates seamlessly with smart wearables and hearables using Photoplethysmography (PPG) sensors to your glucose status. UKRIDA’s interest in developing healthcare based on innovative technology has found BGEM to have great potential in glucose metabolism evaluation and control, especially since diabetes mellitus is one of the major metabolic diseases that needs to be prevented and controlled. The joint project with Actxa to further develop BGEM capabilities and adapt them to the Indonesian population will enable UKRIDA to be a pioneer in chronic disease prevention and control technology in Indonesia. ​ This strategic partnership enables Actxa and UKRIDA, with its motto “Lead to Impact”, to jointly pioneer research and development initiatives leveraging cutting-edge technologies such as AI, Machine Learning (“ML”), and Big Data Analytics. Their collaborative efforts aim to detect, delay, or prevent the onset of chronic diseases. This alliance fosters innovation through the co-creation of healthcare solutions and advanced technologies, coupled with rapid prototyping, to accelerate the market introduction of these products and technologies. Marcus Soo, Chief Executive Officer of Actxa, said, “We are honoured to partner with UKRIDA, marking a significant milestone for Actxa as we embark on our very first collaboration with an Indonesian university conducting research within a hospital setting. This partnership reflects our shared commitment to innovation and empowering individuals with tools to make informed and positive lifestyle decisions. We extend our gratitude to our joint venture partner, LIF, for their pivotal role in this close partnership, facilitating our efforts in Indonesia. Together, we aim to drive global innovation in preventive healthcare, leveraging our combined expertise to make meaningful strides in chronic disease prevention and management.” Prof. Dr.-Ing. Ir. Herman Parung, M.Eng, Rector of UKRDIA, shared, “Both Actxa and UKRIDA share a profound commitment to innovation and the advancement of preventive healthcare solutions. This partnership is poised to accelerate the development of advanced healthcare solutions, ultimately contributing to better health and well-being for individuals and communities.” He also added, “We are confident that this partnership will yield significant advancements in healthcare and foster a strong bond between our institutions.” This partnership between Actxa and UKRIDA heralds groundbreaking innovations in chronic disease prevention and management, working towards building a healthier future for individuals in Singapore, Indonesia, and worldwide. This joint project will also be an example of UKRIDA’s commitment to developing health science based on innovative technology and its effort to build strategic partners from national, regional, and international circles to bring greater progress and benefit to society. For further information, please contact: ​Tan Lay Eng Communications Manager layeng.tan@actxa.com +65 9877 0406 Hasyimah Begum AJ Communications Executive hasyimah.aj@actxa.com +65 8780 3620  About Actxa Headquartered in Singapore, Actxa Pte Ltd is a deep tech company founded in 2015 that leverages artificial intelligence to create next generation preventive healthcare solutions. We create evidence-based, personalized health insights in the domains of physical activities, sleep quality, body composition, stress and recovery, heart health and blood glucose evaluation and monitoring. ​​ ​Learn more about Actxa at www.actxa.com.

Singapore, 9 November 2024 – Actxa, a Singapore-based deep tech company, showcased its cutting-edge solutions at World Diabetes Day 2024, organised by Diabetes Singapore at Toa Payoh HDB Hub Mall on 9 and 10 November. Over the weekend, Actxa featured its BGEM technology – the world’s first non-invasive solution for glucose awareness by a cloud-based AI-driven algorithm. The event was graced by Ms Rahayu Mahzam, Minister of State, Ministry of Digital Development and Information & Ministry of Health, as the Guest of Honour, emphasising the critical importance of combating diabetes in Singapore. Non-Invasive Glucose Monitoring with BGEM Technology At the heart of Actxa’s booth was BGEM® technology, which introduces a non-invasive approach to glucose awareness. BGEM® leverages wearables with photoplethysmography (“PPG”) sensors to collect physiological signals, while an AI model analyses relevant digital biomarkers associated with glucose-related patterns. By making glucose-related insights more accessible, BGEM® is designed to help individuals build greater awareness of their bodies and understand how everyday factors such as meals, activity, sleep and other lifestyle habits may influence their wellbeing. During the two-day event, attendees had the opportunity to experience live demonstrations of the BGEM® solution using smart rings, showcasing how non-invasive wearable technology can provide convenient glucose-related insights within minutes. Transforming Health with Preventive Technology Marcus Soo, Chief Executive Officer of Actxa, said, "Actxa is excited to be a gold sponsor at World Diabetes Day 2024 as we continue our journey to translate technological innovations into evident solutions that enhance lives. Diabetes remains one of Singapore's most urgent public health challenges and we are committed to making an impact. BGEM exemplifies our dedication to providing tools that empower people to make proactive health choices. We envision a future where managing chronic conditions like diabetes is made more attainable for all, building healthier communities together.” Other Key Highlights from Actxa’s Booth · Health Insights with the Sense 2 Smart Scale: Attendees received free body composition analysis reports, including body fat percentage, muscle mass, and metabolic rate, that empower them to restructure their lifestyle habits and achieve their desired health goals. · Exclusive Product Discounts: Special event discounts on Actxa’s products, including the Spark+ Series 2 activity trackers and Sense 2 Smart Scale, were offered to support individuals’ journey toward better health. Download event photos here. For further information, please contact: ​Tan Lay Eng Communications Manager layeng.tan@actxa.com +65 9877 0406 Hasyimah Begum AJ Communications Executive hasyimah.aj@actxa.com +65 8780 3620  About Actxa Headquartered in Singapore, Actxa Pte Ltd is a deep tech company founded in 2015 that leverages artificial intelligence to create next generation preventive healthcare solutions. ​ We create evidence-based, personalised health insights in the domains of physical activities, sleep quality, body composition, stress and recovery, heart health and blood glucose evaluation and monitoring. ​​ ​Learn more about Actxa at www.actxa.com.

A local study shows that sensors commonly found in wearables can aid in the non-invasive detection of elevated blood glucose levels (Image source: Stock image) Singapore, 10 October 2024 – Imagine gaining greater awareness of your glucose levels through a wearable device, helping you better understand how your body responds and supporting more informed everyday lifestyle choices. Type 2 diabetes mellitus (T2DM) is a major global non-communicable disease, with cases rising from 108 million in 1980 to 422 million in 2014[1]. Recognising the growing importance of glucose awareness and more accessible health insights, Actxa Pte Ltd (Actxa) partnered with KK Women’s and Children’s Hospital (KKH) on a research study. The study, “Utility of photoplethysmography in detecting elevated blood glucose among non-diabetics”, recently published in the Singapore Medical Journal, explored the use of photoplethysmography (PPG) signals, the optical signals commonly used by wearables to measure heart rate, as a non-invasive method for identifying elevated blood glucose. The findings highlight the potential of PPG technology to provide a more accessible and cost-effective approach to understanding glucose-related physiological signals. The full study can be accessed here. From October 2021 to February 2023, healthy volunteers were recruited at KKH. 483 volunteers’ capillary glucose levels were measured alongside PPG signals using Actxa’s Spark + Series 2 activity tracker and an in-ear wearable. The volunteers were evaluated over eight minutes to obtain accurate PPG readings. Participants with capillary glucose levels of 11.1 mmol/dL or less consumed a standard glucose tolerance drink (TRUTOL. 75 g) and returned one hour later for a follow-up test. In contrast, those with readings exceeding 11.1 mmol/dL were exempted from the glucose tolerance drink. This methodology ensured the thorough evaluation of blood glucose levels, thereby enhancing the reliability of the study’s findings. The research demonstrates how PPG sensors can be used to study elevated blood glucose non-invasively. By exploring how physiological signals captured through wearable devices relate to glucose levels, the study contributes to ongoing research into making glucose-related insights more accessible outside traditional measurement methods. Greater glucose awareness may also help individuals better understand how everyday factors such as meals, physical activity, sleep and other lifestyle habits can influence their bodies. The study also demonstrates the underlying research supporting Actxa’s BGEM® technology. BGEM® is an AI-driven, cloud-based technology that analyses physiological signals collected through PPG-enabled wearable devices to generate glucose-related insights. By integrating BGEM® into wearable technology, Actxa is exploring how non-invasive glucose awareness can become a more convenient part of everyday health monitoring. As healthcare systems worldwide face increasing challenges associated with metabolic health and diabetes, technologies that make health insights more accessible may help individuals become more engaged with their wellbeing. Providing greater awareness of glucose-related patterns can encourage people to reflect on their everyday habits and make more informed choices around nutrition, physical activity, sleep and overall lifestyle. Marcus Soo, Chief Executive Officer of Actxa, said, “In our pursuit of innovative solutions to address global health challenges, Actxa is proud that our technology has been explored through a local research study. This research demonstrates the potential of PPG signals to provide meaningful glucose-related insights through non-invasive wearable technology. Actxa’s BGEM® technology integrates with PPG-enabled wearables to provide a scalable approach to glucose awareness, helping us explore new ways to make everyday health insights more accessible. The opportunity lies in enabling wearable devices on the wrist, finger or ear to help individuals better understand glucose-related patterns and how their daily habits may influence their wellbeing. This collaboration reflects our commitment to advancing preventive health technology and empowering individuals with accessible insights that can support healthier everyday choices. Together with our partners, we are working towards a future where understanding your health becomes simpler and more integrated into everyday life.” Future developments will involve incorporating various non-invasive detection sensors to enhance sensitivity and specificity, enabling better management of T2DM through non-invasive methods alongside capillary glucose measurements. Reference: 1. WHO Factsheet on Diabetes: https://www.who.int/news-room/fact-sheets/detail/diabetes For further information, please contact: ​Tan Lay Eng Communications Manager layeng.tan@actxa.com +65 9877 0406 Hasyimah Begum AJ Communications Executive hasyimah.aj@actxa.com +65 8780 3620  About Actxa Headquartered in Singapore, Actxa Pte Ltd is a deep tech company founded in 2015 that leverages artificial intelligence to create next generation preventive healthcare solutions. ​ We create evidence-based, personalised health insights in the domains of physical activities, sleep quality, body composition, stress and recovery, heart health and blood glucose evaluation and monitoring. ​​ ​Learn more about Actxa at www.actxa.com.

The Actxa Core is an innovative and affordable smart ring bogged down by red tape. Photo: HWZ I wrote about the Actxa Core smart ring when it was first announced, and I was genuinely excited because of a unique feature called BGEM (Blood Glucose Evaluation and Monitoring). BGEM is the world’s first non-invasive AI-powered glucose evaluation technology developed by Actxa, making the Core smart ring the first consumer wearable to feature this technology. Blood Glucose Evaluation Technology Prior to this, BGEM had undergone a joint study with KK Women’s and Children’s Hospital that’s published in the Singapore Medical Journal titled, “Utility of photoplethysmography in detecting elevated blood glucose among non-diabetics”. There have also been other international clinical trials as well as a published scientific paper titled, “Assessing Elevated Blood Glucose Levels Through Blood Glucose Evaluation and Monitoring Using Machine Learning and Wearable Photoplethysmography Sensors: Algorithm Development and Validation”. BGEM makes use of the standard PPG sensor of most wearables (the active optical sensor you often see on the back of these devices) and uses Actxa’s proprietary AI model to compute certain biomarkers to determine glucose status. Among the now-mature smart wearable market, BGEM was a breath of fresh air. I’ve written about wearables and advancing sensor technology in past reviews, where actionable data matters more than another cryptic stat (for reference, check out my Amazfit Balance smartwatch review). BGEM® takes a similar approach by providing a simple, easy-to-understand result that can help users become more aware of their glucose patterns. It is a feature with broad relevance, offering another way to understand how everyday factors such as diet, activity, sleep and other lifestyle habits may influence overall wellbeing. To start, you simply the BGEM test from the Actxa app 3 times within a 7-day window. As with any blood glucose assessment, it’s best you do it in a fasted state, but if you’re in doubt, the app provides all the necessary guidance. The test itself is simple since it’s non-invasive and takes only a minute to complete. Design & Capablities So, I’ve spent a good chunk of this review writing about BGEM. How about the Core ring itself? Well, it’s Actxa’s first smart ring, and specs-wise, it matches most of the popular ones you can buy in Singapore, like the Samsung Galaxy Ring, Ultrahuman Ring Air and RingConn Smart Ring. It is made of aerospace-grade titanium for durability, just 2.2mm thin and between 2.5g-3.2g in weight depending on ring size. Now, I’m not sure about the Galaxy Ring and Ultrahuman, but I’ve tested the RingConn Gen 1 and Gen 2, and the Actxa Core ring is comparable in size, weight and feel. However, in terms of design, I prefer the RingConn Gen 2 as it is angular on the outside, which makes it seem thinner than it is, especially in the space between fingers if you wear multiple rings. The Actxa Core ring is fully rounded, and I find that it knocks against the ring adjacent to it. A small matter, and it is up to user preferences. There’s a deliberate design indent on the ring to let you know where the sensor is without having to look at it. Photo: HWZ Quick comparison between the Actxa Core (on index finger), and RingConn Gen 2 (middle finger). At night, the Core’s sensor light is brighter and leaks more. Photo: HWZ The Actxa Core also has all the standard sensors and health monitoring we’ve come to expect, including all-day heart-rate monitoring with heart-rate variability (HRV) for stress detection, SpO2, VO2 Max, skin temperature variation, and sleep stages. It does not however feature Sleep Apnea detection like the RingConn Gen 2 or women’s health and cycle detection like the Ultrahuman Ring Air. The Ultrahuman Ring also has AFib detection features too, but again, that’s unavailable due to the lack of regulatory approvals. The Actxa Core has all the sensors expected of a modern health and activity tracker. Photo: HWZ I spoke with Actxa, and they’ve mentioned that some of these features such as cycle tracking are in the works and may be added in the future, but otherwise, the Core smart ring is as complete as any of its competitors for general daily health tracking. It supports a range of workouts as well, including runs, walks, cycling, and generic workout tracking, which basically bumps up the sensor for real-time tracking. By default, the Core (and most smart rings) operate on a periodic cycle (which can be changed in the app for more frequent scanning, though this will impact battery life). This is to be expected considering how small rings are and to conserve battery. The fact that the Core ring lasts longer than most smartwatches is already a big plus for anyone looking to just have health insights. Out of the box, I’ve gotten the Core ring to last about 5 full days and nights with 1-2 workouts per week. I can stretch it to the 6th day on most occasions, but I prefer to have it charged on day 5 before I go to sleep. The Actxa Core charging dock looks like a case, but does not have its own battery; it’s just a dock and has to be plugged in to charge the ring. Photo: HWZ App Experience & Stats Reporting The only thing holding the Core back is, of course, software experience, and the Actxa app isn’t as comprehensive as the competition. The good thing is that it doesn’t require any subscription to activate or use any of its features, but it’s quite barebones. You get a simple view of your activity and summary, and that’s all most people need, but the app’s not the most friendly if you’re looking at deep-diving into your history. Accessing past data is not very intuitive as the dashboard forces you to manually click through every single day—at least I haven’t found an option to just pick a date or a calendar view. Weekly and monthly summaries are available, but you can’t click into individual days from there. Workout and sleep data logs can be accessed, but they’re hidden under multiple layers of sub-menus. Actxa app will give you most info at a glance, but not very intuitive if you want to jump to different dates and get quick insights or comparisons. Screenshot: HWZ Workout data is otherwise solid. Screenshot: HWZ Conclusion So, even though BGEM is not yet available in Singapore and its app can use some sprucing up, the Actxa Core ring is competent as a health tracker and comparable with the competition in terms of design, weight, battery life. The biggest plus point is that it’s almost S$100 cheaper than either the Samsung Galaxy Ring, Ultrahuman Ring Air or RingConn Gen 2; all three currently retail around the S$440-450 price point. Actxa is asking for just S$349 for the Core smart ring, which makes it an incredibly attractive option, and when (not if) BGEM is finally approved for use, it will be one of the most useful personal smart health tools to have on hand…or finger. Actxa Core smart ring and it’s charging dock. Photo: HWZ You can buy the Actxa Core smart ring on their webstore or Lazada. View the article here: Actxa Core review: Is this Singapore-made smart ring any good?

(Media Source: Lianhe Zaobao) 本地保健科技品牌Actxa推出首款智能戒指 Core Smart Ring，以简约设计与轻盈钛合金打造，适合全天佩戴。 这款智能戒指具备多项保健功能，帮助监测休息品质，包括追踪睡眠不同阶段，提供全天血氧监测，心率变异与压力侦测及三重温度感应，以侦测体温细微变化，反映免疫、恢复或荷尔蒙情况。它也能动态扫描血糖变化，追踪最大摄氧量（VO2 Max），测量心肺健康，并智能记录运动强度。 此戒指可与Actxa手机应用软件无缝连接，提供全方位健康记录，有哑光黑（matt black）与哑光银（matt silver）两种颜色选择。该产品将于9月中正式推出，并在9月3日至14日于Lazada LazMall抢先举行特别预购活动。 售价：$349（预购活动优惠价$299） 售于：Actxa官网（actxa.com）、Shopee和Lazada